Clinical trial NCT06169865: Prevalence of Peripheral Vascular Diseases and Presentation in Patients With Autoimmune Diseases
Official title: Prevalence of Peripheral Vascular Diseases and Presentation in Patients With Autoimmune Diseases
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Peripheral Vascular Diseases and Presentation in Patient With Autoimmune Diseases
Lead sponsor: Sohag University
Sponsor class: OTHER
First posted: 2023-12-14
Enrollment: 300
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: * All ages
* Both sexes
* Recent or past history of vascular diseases or presentation in any proven autoimmune diseases according to the guidlines.

Brief summary: Rheumatic autoimmune diseases include conditions such as systemic lupus rheumatoid arthritis systemic sclerosis in which connective tissues are frequently targeted.

Autoimmune diseases as a group are among the leading causes of death and morbidity in the industrial world and pose an immense socioeconomic burden despite the considerable accumulative burden of these diseases only a small number of multinational registries for a few selected autoimmune diseases have been devised.

Numerous autoimmune inflammatory diseases have been associated with various forms of vasculopathy and increase vascular disease risk such as accelerated atherogenesis and thromboembolic events as digital and acral gangrene secondary Raynaud syndrome arterial aneurysm and different cutaneous ulcer.

The etiopathogenesis os increased risk of peripheral vascular diseases and presentation in autoimmune diseases is not entirely clear but multiple contibutors have been explored especially in the context of systemic inflammation and disordered thrombogenesis.


Eligibility criteria: Inclusion Criteria:

* all ages
* Both sexes
* Recent or past history of vascular diseases or presentation in any proven autoimmune diseases according to the guidlines.

Exclusion Criteria:

* patients refuse the study
* patients do not have established diagnosis of vascular diseases .
* patients not completely approved to have autoimmune diseases.

Primary outcomes:
measure: prevalence of peripheral vascular diseases and presentations in patients with autoimmune diseases .
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Sohag
country: Egypt
facility: Sohag university Hospital
Study officials:
References:
citation: Cooper GS, Bynum ML, Somers EC. Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases. J Autoimmun. 2009 Nov-Dec;33(3-4):197-207. doi: 10.1016/j.jaut.2009.09.008. Epub 2009 Oct 9.
citation: Zoller B, Li X, Sundquist J, Sundquist K. Autoimmune diseases and venous thromboembolism: a review of the literature. Am J Cardiovasc Dis. 2012;2(3):171-83. Epub 2012 Jul 25.
citation: Bashal F. Thrombosis in Rheumatological Diseases. 2021 Jan 6. In: Almoallim H, Cheikh M, editors. Skills in Rheumatology [Internet]. Singapore: Springer; 2021. Chapter 12. Available from http://www.ncbi.nlm.nih.gov/books/NBK585742/
citation: Pyrpasopoulou A, Chatzimichailidou S, Aslanidis S. Vascular disease in systemic lupus erythematosus. Autoimmune Dis. 2012;2012:876456. doi: 10.1155/2012/876456. Epub 2012 Aug 22.